IQVIA (NYSE:IQV) Shares Down 12.5% – Time to Sell?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price fell 12.5% during trading on Tuesday . The company traded as low as $203.48 and last traded at $202.3190. 3,440,167 shares traded hands during mid-day trading, an increase of 161% from the average session volume of 1,316,846 shares. The stock had previously closed at $231.23.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. BMO Capital Markets began coverage on IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target on the stock. Evercore ISI increased their target price on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Morgan Stanley lifted their price objective on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. TD Cowen upped their target price on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Finally, UBS Group lifted their price target on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Stock Performance

The firm has a market cap of $34.63 billion, a P/E ratio of 27.89, a P/E/G ratio of 2.34 and a beta of 1.36. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The business has a fifty day simple moving average of $231.00 and a 200-day simple moving average of $209.37.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Claret Asset Management Corp raised its stake in IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after buying an additional 49 shares during the last quarter. Versant Capital Management Inc raised its holdings in IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after buying an additional 53 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its holdings in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after buying an additional 58 shares during the last quarter. Brookstone Capital Management increased its position in shares of IQVIA by 2.2% during the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after acquiring an additional 63 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.